Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MedDay Pharmaceuticals SA
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis criteria of secondary or primary progressive MS with clinical evidence of spastic paraparesis fulfilling revised McDonald criteria (2010) and Lublin criteria (1996)
Progression of the EDSS during the past two years of at least 1 point if EDSS from 4.5 to 5.5 and at least 0.5 point if EDSS from 6 to 7
EDSS score from 4.5 to 7 (measured away from a relapse and confirmed at 6 months)
Informed consent prior to any study procedure
Patient aged 18-75 years
You may not be if
Any general chronic handicapping disease other than MS
Intensive physical therapy program within the 3 months prior to inclusion
Impossibility to perform the TW25 test
New treatment introduced less than 3 months prior to inclusion or less than 1 month for Fampridine
Pregnancy or woman with childbearing potential without contraception
Evidence of inflammatory activity of the disease defined as "clinical evidence of a relapse during the year before inclusion or evidence of new gadolinium-enhanced lesions on a brain MRI performed the year before inclusion."
Clareo Health | Effect of MD1003 in Spinal Progressive Multiple Sclerosis
